BioCentury
ARTICLE | Clinical News

VX-680: Suspended Phase I enrollment

December 3, 2007 8:00 AM UTC

Vertex Pharmaceuticals Inc. (VRTX), Cambridge, Mass. Merck & Co. Inc. (MRK), Whitehouse Station, N.J. Product: VX-680, MK-0457 Business: Cancer Molecular target: FMS-like tyrosine kinase 3 ( FLT3) D...